BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 33217509)

  • 1. Changing spectrum of suspected drugs of epidermal necrolysis: A World Health Organization pharmacovigilance database analysis from 1997-2020.
    Bettuzzi T; Ingen-Housz-Oro S; Purtillo CC; Le Cleach L; Maison P; de Prost N; Wolkenstein P; Lebrun-Vignes B; Sbidian E
    J Am Acad Dermatol; 2021 Dec; 85(6):1581-1584. PubMed ID: 33217509
    [No Abstract]   [Full Text] [Related]  

  • 2. Biases associated with epidermal necrolysis reporting in pharmacovigilance: An exploratory analysis using World Health Organization VigiBase.
    Bettuzzi T; Ingen-Housz-Oro S; Maison P; de Prost N; Wolkenstein P; Lebrun-Vignes B; Sbidian E
    Pharmacoepidemiol Drug Saf; 2022 Apr; 31(4):434-441. PubMed ID: 34907614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse events associated with dupilumab in the World Health Organization pharmacovigilance database.
    Bettuzzi T; Drucker A; Staumont-Sallé D; Bihan K; Lebrun-Vignes B; Sbidian E
    J Am Acad Dermatol; 2022 Feb; 86(2):431-433. PubMed ID: 34600034
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs in pediatric patients: Subgroup analysis based on a Japanese spontaneous database.
    Inada A; Oyama S; Niinomi I; Wakabayashi T; Iwanaga K; Hosohata K
    J Clin Pharm Ther; 2019 Oct; 44(5):775-779. PubMed ID: 31231846
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is acetaminophen associated with a risk of Stevens-Johnson syndrome and toxic epidermal necrolysis? Analysis of the French Pharmacovigilance Database.
    Lebrun-Vignes B; Guy C; Jean-Pastor MJ; Gras-Champel V; Zenut M;
    Br J Clin Pharmacol; 2018 Feb; 84(2):331-338. PubMed ID: 28963996
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in vietnamese spontaneous adverse drug reaction database: A subgroup approach to disproportionality analysis.
    Nguyen KD; Tran TN; Nguyen MT; Nguyen HA; Nguyen HA; Vu DH; Nguyen VD; Bagheri H
    J Clin Pharm Ther; 2019 Feb; 44(1):69-77. PubMed ID: 30129156
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stevens-Johnson syndrome and toxic epidermal necrolysis with antiepileptic drugs: An analysis of the US Food and Drug Administration Adverse Event Reporting System.
    Borrelli EP; Lee EY; Descoteaux AM; Kogut SJ; Caffrey AR
    Epilepsia; 2018 Dec; 59(12):2318-2324. PubMed ID: 30395352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Drug-induced Stevens-Johnson syndrome: a disproportionality analysis from the pharmacovigilance database of the World Health Organization.
    Zheng Y; Zhou W; Guo X; Chi L; Chen C; Guo Z; Liang J; Wei L; Chen X; Ye X; He J
    Expert Opin Drug Saf; 2022 Aug; 21(8):1127-1133. PubMed ID: 35196201
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatal adverse drug reactions: A worldwide perspective in the World Health Organization pharmacovigilance database.
    Montastruc JL; Lafaurie M; de Canecaude C; Durrieu G; Sommet A; Montastruc F; Bagheri H
    Br J Clin Pharmacol; 2021 Nov; 87(11):4334-4340. PubMed ID: 33837554
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poor reporting and documentation in drug-associated Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis - Lessons for medication safety.
    Goldblatt C; Khumra S; Booth J; Urbancic K; Grayson ML; Trubiano JA
    Br J Clin Pharmacol; 2017 Feb; 83(2):224-226. PubMed ID: 27558920
    [No Abstract]   [Full Text] [Related]  

  • 11. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase.
    Motola D; Donati M; Biagi C; Calamelli E; Cipriani F; Melis M; Monaco L; Vaccheri A; Ricci G
    Pharmacoepidemiol Drug Saf; 2017 Oct; 26(10):1164-1171. PubMed ID: 28653802
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse Cutaneous Drug Reactions Associated with Old- and New- Generation Antiepileptic Drugs Using the Japanese Pharmacovigilance Database.
    Hosohata K; Inada A; Oyama S; Niinomi I; Wakabayashi T; Iwanaga K
    Clin Drug Investig; 2019 Apr; 39(4):363-368. PubMed ID: 30689189
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spontaneous adverse event reports of Stevens-Johnson syndrome/toxic epidermal necrolysis: detecting associations with medications.
    Papay J; Yuen N; Powell G; Mockenhaupt M; Bogenrieder T
    Pharmacoepidemiol Drug Saf; 2012 Mar; 21(3):289-96. PubMed ID: 22139991
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
    Ortland I; Mirjalili M; Kullak-Ublick GA; Peymani P
    Swiss Med Wkly; 2021 May; 151():w20503. PubMed ID: 34000058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stevens-Johnson syndrome and toxic epidermal necrolysis: the Food and Drug Administration adverse event reporting system, 2004-2013.
    Abe J; Mataki K; Umetsu R; Ueda N; Kato Y; Nakayama Y; Kinosada Y; Hara H; Inagaki N; Nakamura M
    Allergol Int; 2015 Jul; 64(3):277-9. PubMed ID: 26117261
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessing carbamazepine and oxcarbazepine-associated Stevens-Johnson syndrome/toxic epidermal necrolysis: Data mining the public version of the FDA adverse event reporting system.
    Xu C; Pan L; Zhang Y; Zhang J; Sun Q; Fang W
    Int J Clin Pract; 2021 Aug; 75(8):e14273. PubMed ID: 33908133
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antiepileptic combination therapy with Stevens-Johnson syndrome and toxic epidermal necrolysis: Analysis of a Japanese pharmacovigilance database.
    Noguchi Y; Takaoka M; Hayashi T; Tachi T; Teramachi H
    Epilepsia; 2020 Sep; 61(9):1979-1989. PubMed ID: 32761907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of reporting of Stevens-Johnson syndrome and toxic epidermal necrolysis in association with selective COX-2 inhibitors.
    La Grenade L; Lee L; Weaver J; Bonnel R; Karwoski C; Governale L; Brinker A
    Drug Saf; 2005; 28(10):917-24. PubMed ID: 16180941
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety profile of erenumab, galcanezumab and fremanezumab in pregnancy and lactation: Analysis of the WHO pharmacovigilance database.
    Noseda R; Bedussi F; Gobbi C; Zecca C; Ceschi A
    Cephalalgia; 2021 Jun; 41(7):789-798. PubMed ID: 33435709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis among new users of different individual drugs in a European population: a case-population study.
    Rodríguez-Martín S; Martín-Merino E; Lerma V; Rodríguez-Miguel A; González O; González-Herrada C; Ramírez E; Bellón T; de Abajo FJ
    Eur J Clin Pharmacol; 2019 Feb; 75(2):237-246. PubMed ID: 30298362
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.